Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$1.60
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.60
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.18 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.52M
Market Cap
$401.90M
Enterprise Value$356.23M
Total Cash (Recent Filing)$229.43M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume1,138,944
30 Day Avg. Volume1,522,482
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit-34.38
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$8.08Price Target Upside405.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$129.44M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained, rapid revenue growth from the AUCATZYL U.S. launch and initial U.K. roll-out demonstrates real commercial traction and adoption. Reiterated full‑year guidance and expanding active treatment centers (>73, >80 planned) imply durable top‑line expansion as volume scales and payer access matures.
Improving Unit EconomicsA positive gross profit quarter plus explicit targets for high peak gross margins indicate the product can reach attractive unit economics as manufacturing and process optimizations scale. Doubling planned production in 2026 with staffing near prior levels supports sustainable margin improvement over the medium term.
Strong Clinical & Real‑World DataRobust safety and efficacy in real‑world cohorts strengthens clinical differentiation and payer/physician confidence, aiding durable market access and expansion into pediatric and other indications. A broad pipeline with multiple readouts supports product diversification and longer‑term revenue resilience beyond the initial ALL franchise.
Bears Say
High Cash Burn / Runway RiskSizable negative operating and free cash flows, coupled with cash running to Q4‑2027, create a persistent financing overhang. Continued burn forces reliance on capital markets or dilution to fund commercialization and trials, elevating long‑term funding and execution risk if revenue or cost improvements disappoint.
Persistent Large LossesVery large negative margins and returns reflect a cost structure far ahead of current revenues. Although margins are improving, sustained heavy losses constrain reinvestment flexibility, increase dilution risk, and delay company‑level profitability, making long‑term value creation dependent on successful scale and margin realization.
Manufacturing & Market Access Execution RiskPlanned capacity increases and third‑party manufacturing transfers are critical to meeting volume and cost targets. Unproven tech transfer and ongoing European access discussions create durable execution risk: failures or delays would impair unit economics, slow international revenue diversification, and keep commercial costs elevated.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.18 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $401.90M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 38 days.
How were Autolus Therapeutics’s earnings last quarter?
Autolus Therapeutics released its earnings results on May 14, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.017.
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,155,800 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Autolus Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went down -7.018%.
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.08 (405.00% Upside)
$8.08 (405.00% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.69%
12-Months-Change
Fundamentals
Return on Equity
-128.53%
Trailing 12-Months
Asset Growth
-29.38%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected strong commercial momentum and operational progress: quarterly revenue surged (~191% YoY), the company achieved its first positive gross margin quarter, and production efficiency initiatives target lower per-unit costs and $15M annualized savings in 2027. Real-world data and multiple near- and mid-term clinical readouts underpin a promising pipeline and support expansion into new indications and geographies. Offsetting these positives are continued high net losses, significant cash drawdown (cash runway into Q4 2027), a sizable rise in SG&A to support commercialization, and execution risks related to manufacturing scale-up and European market access. Overall, while financial and execution risks remain, the balance of substantial commercial progress, margin improvement, and clear pipeline milestones leads to a constructive outlook.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.08
▲(405.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
40.45% Other Institutional Investors
58.50% Public Companies and
Individual Investors